The drug late last year received accelerated approval from the FDA in CLL based on findings from the phase I/II BRUIN trial, which demonstrated deep responses with the drug, including in patients ...

There are four types of BTK inhibitors currently used to treat CLL: All four BTK inhibitors are taken orally as a pill or capsule, once or twice a day, depending on the drug. BTK inhibitors may be ...

An FDA decision on the approval of ofatumumab for CLL is anticipated at the end of ... to these results include the site at which the drugs bind to CD20. “Ofatumumab binds on a site which ...

Researchers have revealed a new finding that could improve cancer care immunotherapy treatments, particularly for CLL and ...

It is leading to improved survival rates in CLL and I think as we move into first line, in patients who have not been treated, we are likely to see some better responses.” The drug gained a ...

People with CLL have a life expectancy of more than two years, so did not meet NICE’s criteria. It is also not suitable for the Cancer Drugs Fund, which can provide interim reimbursement if ...

It is important for people living with chronic lymphocytic leukemia (CLL) to take care of their mental and physical health. Tips to manage day-to-day include getting enough rest and talking with ...

Treatment options can include chemotherapy, targeted drugs, immunotherapy, and bone marrow transplant. For more information about chronic lymphocytic leukemia, talk to your doctor. [MUSIC PLAYING] ...

The drug has been approved for relapsed/refractory (r/r) CLL/SLL, r/r marginal zone lymphoma and r/r mantle cell lymphoma on China's National Reimbursement Drug List. InnoCare Pharma focuses on ...

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer that affects white blood cells. Survival rates tend to be high, but these may vary. Leukemia is a type of cancer involving human blood ...

You can be your own best advocate when you have CLL. Learn how to get educated about your cancer and speak effectively to your doctor.

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...